|1.||Koepsell, Hermann: 3 articles (02/2014 - 05/2004)|
|2.||Becker, M L: 2 articles (06/2015 - 08/2009)|
|3.||van Schaik, R H N: 2 articles (06/2015 - 08/2009)|
|4.||Fardel, Olivier: 2 articles (03/2014 - 08/2011)|
|5.||Jouan, Elodie: 2 articles (03/2014 - 08/2011)|
|6.||Le Vee, Marc: 2 articles (03/2014 - 08/2011)|
|7.||Sparreboom, Alex: 2 articles (02/2014 - 05/2008)|
|8.||Hu, Shuiying: 2 articles (02/2014 - 05/2008)|
|9.||Baker, Sharyn D: 2 articles (02/2014 - 05/2008)|
|10.||Clark, Richard E: 2 articles (10/2012 - 10/2008)|
|1.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
09/01/2011 - "The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia."
08/01/2014 - "The aim of the study was to investigate any possible influence of polymorphisms of transmembrane transporters human organic cation transporter 1 (hOCT1), ABCB1, ABCG2 on imatinib pharmacokinetics in 33 men and 27 women (median age and range, 56 and 27-79 years, respectively) affected by chronic myeloid leukemia. "
01/01/2015 - "Human organic cation transporter 1 protein levels of granulocytes can optimize imatinib therapy in patients with chronic myeloid leukemia."
10/01/2012 - "Low pretreatment expression of the imatinib uptake transporter human organic cation transporter 1 (hOCT1) is associated with inferior complete cytogenetic response rates, progression-free survival, and overall survival in imatinib-treated chronic myeloid leukemia (CML). "
06/01/2012 - "The functional activity of the organic cation transporter 1 (OCT-1) protein (OCT-1 activity) is an excellent predictor of molecular response and progression-free survival in patients with newly diagnosed chronic phase chronic myeloid leukemia treated with imatinib as front-line therapy. "
|2.||Crohn Disease (Crohn's Disease)
01/01/2012 - "Although a number of genetic studies have attempted to link organic cation transporter 1/2 (OCTN1/2) polymorphisms to susceptibility of Crohn's disease (CD), the results were often inconsistent. "
03/01/2013 - "To investigate the associations between polymorphisms of organic cation transporter OCTN1/2 (organic cation transporter 1/2) and the susceptibility of Crohn's disease (CD) through a meta-analysis. "
|3.||Prostatic Neoplasms (Prostate Cancer)
06/01/2015 - "This study was initiated to explore the impact of organic cation transporter 1 (OCT1) and multidrug and toxin extrusion transporter 1 (MATE1) genetic polymorphisms on toxicity, and clinical activity of metformin in patients with castration-resistant prostate cancer (CRPC). "
06/01/2015 - "Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)."
|4.||Breast Neoplasms (Breast Cancer)
04/01/2008 - "Specifically, we focused on the efflux transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), and an influx transporter, organic cation transporter 1 (OCT1). "
05/01/2015 - "Other renal transporters (human organic anion-transporting polypeptide 4C1 [OATP4C1], organic cation transporter 2 [OCT2], carnitine/organic cation transporter 1 [OCTN1], multidrug and toxin extrusion protein 1 [MATE1], MATE2-K, multidrug resistance-associated protein 2 [MRP2], MRP4, and breast cancer resistance protein [BCRP], and rat Oct1, Oct2, Octn1, Octn2, Mate1, Mrp2, Mrp4, and Bcrp) showed either ambiguous ability to transport tanshinol or no transport activity. "
01/01/2015 - "We investigated the in vitro transport characteristics of catalposide in HEK293 cells overexpressing organic anion transporter 1 (OAT1), OAT3, organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic cation transporter 1 (OCT1), OCT2, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP). "
07/15/2009 - "We investigated the impact of 16 single nucleotide polymorphisms (SNP) in five genes potentially associated with pharmacogenetics of IM, namely ABCB1, multidrug resistance 1; ABCG2, breast-cancer resistance protein; CYP3A5, cytochrome P450-3A5; SLC22A1, human organic cation transporter 1; and AGP, alpha1-acid glycoprotein. "
04/01/2008 - "Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells."
01/01/2015 - "All tumors expressed organic cation transporter 1, with 90% (35 of 39) exhibiting an Allred score of 5 or higher. "
04/01/2013 - "Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma."
01/01/2012 - "In primary malignant tissue, high Oct1 protein but not mRNA levels strongly correlate with the frequency of CD24(LO)CD44(HI) cancer-initiating cells. "
|4.||Messenger RNA (mRNA)
|5.||Taurocholic Acid (Sodium Taurocholate)
|6.||multidrug resistance-associated protein 2
|7.||Carboxylesterase (Hydrolase S)
|8.||Cytochrome P-450 CYP1A2 (CYP1A2)